All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
SRF231 is granted orphan designation status for the treatment of multiple myeloma
On 30 July 2018, the US Food and Drug Administration (FDA) included SRF231 (anti-CD47) among the list of orphan drugs to be used for treating multiple myeloma (MM) patients (pts).
SRF231 is a fully humanized monoclonal antibody, which targets the transmembrane protein CD47. Although CD47 is found at very low levels in most normal cell types, it is highly expressed by many different types of tumor cells, including myeloma cells. CD47 normally binds to the Signal Regulatory Protein Alpha (SIRPA), preventing cell phagocytosis. SRF231 binding to CD47 inhibits the link between CD47 and SIRPA, promoting phagocytosis and removal of myeloma cells.
Currently, the safety and maximum tolerated dose of SFR231 are being examined in a phase I clinical trial in patients with advanced solid and hematologic cancers.
SRF231’s orphan drug designation will support further investigations carried out by the drug research company Surface Oncology on the treating potential of this drug for MM pts.
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?